Categories Retail, U.S. Markets News

Tyson Foods shares plunge after profit outlook cut, blames Trump’s Tariffs

Tyson Foods (TSN) cut its annual profit forecast, blaming the uncertainty surrounding the brewing trade war as well as volatility in the market conditions, sending the shares of the food processing company down almost 7% on July 30. The stock continued to bleed on Tuesday’s regular trading session also.

As the Trump’s trade battle gets real, US companies are starting to feel the pinch. Meat sector and motorcycle makers were said to be among the worst hit. As the global trade war intensifies the two largest foreign buyers of US meat — Mexico and China — have each applied retaliatory tariff against the US meat pork products. In order to protect their business, companies are now taking strategic measures.

Tyson Foods, which specializes in chicken products, clipped its fiscal 2018 earnings target. The company now expects earnings on an adjusted basis to be around $5.70-6.00 a share compared to the prior estimate of $6.55-6.70.

RELATED: Tyson Foods tumbles on weak Q2 results

The Springdale, Arkansas-based company cut down its guidance due to uncertainty in trade policies, increased tariffs that could negatively impact domestic and export prices — mainly chicken and pork, and increased volatility in the commodity markets.

“The combination of changing global trade policies here and abroad, and the uncertainty of any resolution, have created a challenging market environment of increased volatility, lower prices and oversupply of protein. We will continue to watch these conditions carefully,” said Tom Hayes, CEO.

RELATED: US stocks to open lower as Trump’s tariff changes worry investors

Due to the reduced demand, the unsold meat piles up in the US. According to the Wall Street Journal, nearly 2.5 billion-pound surplus of meat has been piled up. Shares of Tyson Foods continued to trade in the negative territory and hit a new yearly low of $56.79 today.

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top